Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib.

New-generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.